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Abstract
Melatonin (N-acetyl-5-methoxytryptamine, MLT), a hormone synthesized by the pineal 
gland and released at night, has a regulatory role on sleep in vertebrates, including 
humans. It has been shown to have a hypnotic action in animals and humans and it has 
been used as an agent for restoring circadian rhythms, disturbed by jet-lag, shift-work 
or aging. The physiological actions of melatonin in regulating seasonal and circadian 
rhythms are mediated through a family of specific, high affinity G protein-coupled mem-
brane receptors. The beneficial effect of fast-release formulations on sleep initiation may 
come from the high amount of melatonin released immediately after administration, 
while the benefit of the sustained release systems comes from the release of melatonin 
in small dosages during the entire night period. This chapter covers the recent scientific 
work on melatonin modified release formulations.
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1. Introduction
Melatonin (MLT), which was originally discovered in the bovine pineal gland in 1958, is a 
pleiotropic molecule with numerous cellular and physiological functions in vertebrates, 
including humans. MLT’s production is regulated by a multisynaptic pathway from the bio-
logical clock in the suprachiasmatic nucleus (SCN), in the hypothalamus, to the pineal gland. 
The SCN is the primary site for both generation and integration of signals, which regulate 
melatonin’s production by the pineal. Control at this central point ensures the high nocturnal 
concentration and extremely low diurnal melatonin synthesis.
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Melatonin has been shown to have a hypnotic action in animals and humans, and there has 
been considerable recent interest in the therapeutic potential of melatonin and its analogues 
as hypnotics and as agents for restoring circadian rhythms, disturbed by jet-lag, shiftwork, 
and aging. The physiological actions of melatonin in regulating seasonal and circadian 
rhythms are thought to be mediated through a family of specific, high affinity, and G-protein-
coupled cell membrane receptors. One of its main uses is insomnia treatment, particularly 
among the elderly, with up to 50% of people over the age of 65 reporting trouble sleeping. 
Night time insomnia is associated with increased daytime sleepiness, reduced motor and 
cognitive performance, and reduced productivity in the workplace and is an important cause 
of industrial and road traffic accidents. Current hypnotic drugs are recommended only for 
short-term treatment of insomnia, but concerns about “hangover” effects and problems upon 
withdrawal persist. Many people with occasional sleep problems resort to self-medication 
and over-the-counter sales of medicines for sleep problems are increasing rapidly [1].
The administration of exogenous melatonin is effected via different formulations, but at pres-
ent, the most studied is the oral route. Also, there are different dosages of melatonin. Because 
of its pharmacokinetic characteristics, it is necessary to maintain melatonin’s concentration 
for a long time to imitate its physiological release, especially for insomnia treatment. To this 
end, prolonged-release formulations of melatonin have been developed covering the entire 
night cycle and improving sleep disorders. As the toxicology of melatonin’s formulations is 
concerned, very little is known. However, the acute toxicity of melatonin, as seen in both ani-
mal and human studies, is extremely low. Nevertheless, further research needs to be under-
taken, including regulatory studies.
2. Formulations of melatonin
Melatonin is traditionally administered orally in immediate and modified release formula-
tions, but has a poor and variable bioavailability. Apart from per os administration, melatonin 
is currently under research with respect to other routes of administration, such as sublingual, 
transbuccal/transmucosal, and intranasal for topical and systemic exposure, injectables (intra-
venous, i.v. bolus infusion, intramuscular, subcutaneous, and implant), topical preparations, 
and transdermal patches. This chapter aims at presenting an overview of all administration 
routes and different kinds of formulations of melatonin that are currently explored in vitro 
and in vivo, including experimental and clinical studies.
2.1. Melatonin per os immediate release formulations
Per os immediate release formulations imply that the full dose of the drug is absorbed into 
the bloodstream all at once. This pattern of fast released melatonin is most effective when 
against delayed sleep onset [2]. The immediate release dosage forms (fast released, oro-
dispersible, sublingual tablets oral sprays, etc.) are usually administered to patients prior 
to sleep time in order to facilitate sleep onset. A research group has manufactured fast dis-
solving disintegrating tablets containing different dosages of melatonin for administration 
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to pediatric patients that may have potential difficulties taking other oral dosage forms 
[3]. Dosages of 3 and 5 mg were intended for epileptic children, migraine prevention, 
neurodevelopmental disability, sleep disorders, and blindness, whereas dosages of 10 
and 60 mg were used for Duchenne muscular dystrophy. Tablets have been produced 
with excipients for direct compression, having disintegration times of less than 25 s and 
with friability and hardness values that require no special storage or packaging condi-
tions. The results indicated that these orodispersible tablets have been easily produced 
via direct compression, having low costs and optimal galenic assay results. To explore 
the therapeutic potential of melatonin, as an antioxidant agent, researchers have analyzed 
the red blood cell antioxidants and lipid peroxidation after 5 mg/daily immediate-release 
melatonin treatment of elderly with type 2 diabetes patients and healthy elderly subjects 
in comparison with 2 mg/daily sustained-release. The results suggest that both immedi-
ate and sustained release preparations may exert similar therapeutic effects related to 
melatonin’s action as antioxidant [4].
2.2. Melatonin per os modified release formulations
Immediate release oral drug dosage forms are formulated in order to release the active sub-
stance immediately after oral administration. On the other hand, modified-release oral drug 
dosage forms are deliberately modified from those of an immediate release, to achieve a 
desired therapeutic objective or better patient compliance. The term modified release drug 
dosage forms is used to describe formulations that alter the time and/or the rate of release. 
With this in view, scientists have focused on modifying the release of melatonin especially to 
treat conditions that deal with circadian rhythmic disorders, like sleep syndrome, insomnia, 
jet lag, seasonal affective disease, shift work syndrome, etc. [5–7]. Modified-release melatonin 
treatment could be more useful to initiate and maintain sleep, compared with immediate-
release therapy.
Many scientists have focused on different ways to manufacture modified release tablets. 
One of the most common ways is the use of various excipients that facilitate the prolong 
release when tablet manufacturing [8–13]. These excipients usually involve hydroxy-
propylmethylcellulose, polyvinylpyrrolidone, and sodium alginate in various molecular 
weights or forms. Another way to achieve modified release is the production of different 
tablet formulations, like multilayer or bilayer, coated or uncoated tablets [14–16]. Other 
researchers have studied the use of liposomal formulations [17] or nanoparticles [18]. 
Recently, electrospun nanofibrous systems, incorporating melatonin, have been used for its 
modified release [19]. Another way is to employ a variety of techniques, like for example, 
the experimental design [20] in order to facilitate the modified release tablet production 
and therefore, to improve quality of sleep in patients, with minimal side effects. Both in 
the development of these systems and the immediate release formulations, the fact that 
melatonin displays both a circadian and circannual rhythm and is secreted only during 
the night has been taken into account. This physiological rhythm needs to be conserved 
or modulated (advanced, reversed, diminished, or amplified) according to the appropriate 
therapeutic indications.
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2.3. Melatonin sublingual/transbuccal formulations
The oral cavity is a perfect route of administration for both topical and systemic treatment. 
Considering melatonin, research has suggested that it is effective in treating pathologies 
like periodontitis, mucositis, cancers, and cytotoxicity from various drugs or biomaterials. 
Furthermore, melatonin has been observed to enhance osseointegration “functional ankylosis 
(bone adherence)” and bone regeneration, to promote the healing of tooth extraction sockets 
and may also impede the progression of oral cancer [21, 22]. On the other hand, sublingual 
and transbuccal/transmucosal administration of melatonin in the forms of sublingual tablets 
or oral sprays has shown comparable systemic results to other routes of administration.
Many scientists have considered the oral cavity as a route of administering melatonin and 
compared it to other routes. The effect of transdermal, in comparison to oral controlled release 
and oral transmucosal drug delivery systems, on plasma concentrations of melatonin and its 
principal metabolite, 6-sulfatoxymelatonin, was evaluated in 12 human volunteers, using a 
crossover, single dose design. Oral transmucosal delivery provided prompt systemic drug 
levels with less variability than oral or transdermal delivery and no indication of mucosal 
deposition. The results indicated that oral transmucosal delivery was able to mimic the physi-
ological plasma profiles of both melatonin and its principal metabolite [23]. Another study 
involved 60 patients, who were randomly assigned to receive either sublingual melatonin 
(3 mg) or placebo, 60 min before cataract surgery. The dose of 3 mg of melatonin sublin-
gually, 60 min before surgery, was chosen, because the onset of melatonin-induced sedation 
is reported to begin approximately 20–30 min after sublingual administration. The results 
concluded that sublingual melatonin premedication for patients undergoing cataract sur-
gery, under topical anesthesia, reduced the anxiety scores and provided excellent operating 
conditions [24]. A prospective, randomized, double-blinded, placebo-controlled study was 
designed to compare the perioperative effects of different doses of melatonin and midazolam 
[25]. Doses of 0.05, 0.1, or 0.2 mg/kg sublingual midazolam or melatonin or placebo were 
given to 84 women, approximately 100 min before a typical anesthetic. Sedation, anxiety, and 
orientation were quantified before, 10, 30, 60, and 90 min after premedication and 15, 30, 60, 
and 90 min after admission to the recovery room. Patients who received premedication with 
either midazolam or melatonin had a significant decrease in anxiety levels and increase in pre-
operative levels of sedation, compared with control subjects. Premedication with 0.05 mg/kg 
melatonin was associated with preoperative anxiolysis and sedation without the impair-
ment of cognitive and psychomotor skills or affecting the quality of recovery. To evaluate 
the analgesic dose response of the effects of melatonin on pressure and heat pain threshold, 
tolerance, and its possible sedative effects, the research group of Stefani et al. [26] recruited 
61 healthy subjects aged 19–47 years old and placed them randomly into one of four groups: 
placebo, 0.05 mg/kg sublingual melatonin, 0.15 mg/kg sublingual melatonin, or 0.25 mg/kg 
sublingual melatonin. Serum plasma melatonin levels were found to be directly proportional 
to the melatonin doses given to each subject indicating that the sublingual melatonin has a 
well-defined dose-dependent antinociceptive activity. These results provided a correlation 
between the plasma melatonin drug concentration and acute changes in the pain threshold. 
To compare the perioperative effects of melatonin and midazolam, given in premedication, 
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on sedation, orientation, anxiety scores, and psychomotor performance, melatonin 5 mg, 
midazolam 15 mg or placebo was administered 90 min prior to anesthesia, sublingually to 
66 patients undergoing laparoscopic cholecystectomy [27]. Sedation, orientation, and anxiety 
were quantified before 10, 30, 60, and 90 min after premedication and 15, 30, 60 and 90 min 
after admission to the recovery room. The results indicated that melatonin premedication was 
associated with preoperative anxiolysis and sedation without postoperative impairment of 
psychomotor performance.
2.4. Melatonin intranasal formulations
Intranasal administration is a route of administration for drugs used primarily for the treat-
ment of conditions affecting the nasal cavity, but can also be used for cases requiring systemic 
exposure, since drugs can be absorbed into the circulation through the nasal mucosa. This 
kind of systemic administration offers lots of advantages, such as rapid onset of action and 
avoidance of first-pass metabolism [28]. Many researchers have investigated melatonin’s 
intranasal administration and tested their formulations in vitro and in vivo in rats, rabbits, and 
humans.
In another study, the role of inclusion complexes of melatonin with modified cyclodextrins 
(CDs) in order to improve melatonin’s solubility and nasal absorption was investigated [29]. 
The formation of inclusion complex of melatonin with hydroxypropyl β-cyclodextrin (HPβCD) 
and randomly methylated β-cyclodextrin (RMβCD) was demonstrated in solution and solid 
state and both CD’s at 1% w/v concentration were found to improve the nasal permeability 
(the in vitro permeability studies were carried out with EpiAirwayTM-100 cell cultures from 
MatTek Corporation) of melatonin from HPMC gel formulations.
Intranasal melatonin encapsulated in nanosized niosomes has been preclinically evaluated in 
male Wistar rats [30]. It was found that intranasal melatonin niosomes that were bioequiva-
lent to intravenous injection of melatonin could provide therapeutic level doses, deliver 
melatonin to the brain to induce sleep, and delay systemic circulation. The cross-over study, 
including eight rats, examined the intranasal administration of melatonin from a nasal formu-
lation consisted of melatonin (2.0 mg/ml), β-cyclodextrin (7.5 mg/ml) dissolved in saline that 
also contained benzalkonium chloride (0.01% w/v) and EDTA (0.1% w/v) as preservatives, in 
comparison to the administration from an intravenous bolus injection. Tmax was recorded 
at 2.5 min in both routes of administration and an almost zero plasma concentration after 
120 min [31].
In another study, the research group [32] prepared melatonin gelatin microspheres (MLT-
GMS) for intranasal administration and tested them in comparison to gelatin solution and 
i.v. injection. The in vitro release profile showed sustained effect, while the residence time of 
MLT-GMS in the rabbits’ nasal cavity was longer than that of gelatin solution. After intra-
nasal administration in rabbits, the bioavailability of MLT-GMS was 87.47%, while the bio-
availability of melatonin solution was 69.72%, when compared to i.v. administration. The 
results showed that this formulation could meet the needs of intranasal administration, while 
increasing melatonin’s bioavailability. Other scientists have studied the bioavailability of 
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melatonin in rabbits after nasal administration of two formulations (1.5 mg melatonin in 40% 
PEG 300 in the presence and absence of 1% sodium glycocholate) in comparison to the i.v. 
route [33]. The results documented that the bioavailabilities in rabbits correspond to much 
higher values, which indicates a potential advantage of using nasal delivery for melatonin 
and the possibility of producing a clinically relevant nasal formulation. In another study, 
starch microspheres of melatonin for intranasal administration were prepared by an emulsifi-
cation crosslinking technique using a uniform design to optimize preparation conditions [34]. 
The in vitro release experiments showed that melatonin was released from the microspheres 
in a sustained manner. Nasal clearance studies in six healthy, male rabbits showed that >80% 
of the radioactivity from the starch microspheres was present in the nasal mucosa 2 h after 
administration, compared to only 30% radioactivity from the solution. The absorption rate 
after intranasal administration of the microspheres was rapid, and the absolute bioavailability 
was high, compared to the intranasal solution and a significant correlation between in vivo 
and in vitro data was recorded.
In humans, a cross-over study in three volunteers, receiving either intranasally 0.4 mg melato-
nin or intravenously 0.2 mg on two separate study days, was undertaken. The study reported 
a Tmax value of 5 min for intranasal administration and 10 min for intravenous administra-
tion [35]. Other researchers [36] have formulated melatonin, as a thermoreversible Pluronic 
gel for nasal administration for treating sleep disorders. The comparative electroencephalo-
gram (EEG) pattern, derived from five healthy volunteers who participated in this crossover 
study after administration of melatonin tablet and nasal gel, revealed that nasal absorption of 
melatonin was faster and the sleep produced resembled to one during nocturnal chronobio-
logical melatonin secretion. The optimized formulation has provided bimodal drug release 
extending over 5 h at significantly low dose (1 mg intranasal dose) as compared to 3 mg oral 
dose. The use of the novel thermoreversible Pluronic gel showed the desired bioadhesion to 
the nasal mucosa, with no sensitizing effect in subjects and reproducible sleep characteristics 
thus making this formulation an agent with an excellent commercial potential.
2.5. Melatonin injectable formulations
Injectable formulations also play an important role as melatonin modified release systems. 
Many researchers have focused on intravenous (i.v. bolus infusion), intramuscular, subcu-
taneous, and implant administration of melatonin formulations in human volunteers, small 
laboratory animals, as well as in larger animals like ewes, goats, and deer.
A research work showed that during melatonin infusion (n = 4 bolus intravenous injection 
of 5 or 10 μg/person and after a 5-h infusion of 20 μg per person in six healthy subjects), 
the plasma hormone level reached a steady-state after 60 and 120 min, which was equal to 
the nocturnal level. This particular infusion regime could be valuable in replacing blunted 
hormonal secretion in disease states [37]. A human positron emission tomography (PET) 
study, performed in a healthy volunteer with 11C-labeled melatonin, showed maximum 
activity in the brain 8.5 min following the injection, quite different from the curve observed 
for the plasma radioactivity (maximum at 3.5 min), confirming that melatonin crosses the 
blood-brain barrier and that 6-sulfatoxymelatonin is its main plasma metabolite [38]. The 
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absolute bioavailability of melatonin was studied in 12 young healthy subjects (six males and 
six females) after administration at midday, on two separate occasions: 23 μg by intravenous 
infusion and 250 μg by oral solution of D7 melatonin (seven deuterium atoms replace seven 
hydrogen atoms in the melatonin molecule). Exogenous (D7) and endogenous (D0) melato-
nin were quantified simultaneously, but separately, by a highly specific assay, gas chroma-
tography/negative ion chemical ionization mass spectrometry. After i.v. administration, the 
maximum plasma concentration (Cmax) and the area under the plasma concentration-time 
curve (AUC) values were found to be significantly different in male and female subjects, but 
there was no significant gender difference in total body clearance when normalized to body 
weight. After oral administration, pharmacokinetic parameters used to quantify bioavailabil-
ity were near 3 times greater in female subjects than in males, with large inter-individual 
variations [39]. In the review article of Gómez-Moreno et al. [40], the use of melatonin in 
implant dentistry has been proved to increase the new bone formation and bone-to-implant 
values, around dental implants, leading to a more stable bone area around the implants. In 
view of these findings, researchers are currently exploring further possibilities as to how 
melatonin might benefit implant dentistry.
Two i.v. formulations of melatonin (5 mg/ml) have been tested in Wistar rats: one formulation 
with hydroxypropyl-β-cyclodextrin and propylene glycol to increase solubility and stability 
and the other with an antioxidant and chelating agent to minimize oxidation and hydro-
lysis. The pharmacokinetic profiles and the plasma antioxidant activity results suggested a 
potential for use in the clinical study for these two i.v. melatonin formulations [41]. Another 
research group [42] studied the possibility of using high-dose intravenous melatonin as an 
anesthetic adjuvant and compared its effects with thiopental and propofol using Sprague 
Dawley rats. By administering to the rats bolus or cumulative i.v. doses of melatonin, thiopen-
tal, or propofol, they assessed the righting reflex, hind paw withdrawal to a noxious stimu-
lus, response to tail clamping and hemodynamic effects. The results showed that melatonin 
caused a dose-dependent increase in paw withdrawal. Melatonin was comparable to thiopen-
tal and propofol in terms of its rapid onset of hypnosis and it was concluded that intravenous 
melatonin can exert hypnotic effects similar to those observed with thiopental and propofol. 
Other researchers have injected mice daily with 50 μg of melatonin, 12 h after lights on, for 
18 weeks. The results indicated that mice underwent gonadal regression after 4–7 weeks and 
reproductive recrudescence after 15 weeks [43].
The effect of differing doses and routes of administration of melatonin on plasma melatonin 
levels in sheep and goats has been examined by the researchers Kennaway and Seamark [44]. 
Melatonin injected subcutaneously in a saline or oil vehicle caused high transitory peaks in 
plasma melatonin, whereas oral administration, in either saline solution or adsorbed onto 
pelleted foodstuff, resulted in sustained elevated blood levels for periods exceeding 7 h. Oral 
dosages of about 2 mg proved adequate to raise the normal daytime plasma levels in both 
sheep and goats to levels within the normal night-time range. It was concluded that with 
ruminants the oral route of administration provides a facile and practical way of administer-
ing melatonin for physiological study. The review paper of Williams et al. [45] presents data 
from five research trials and 108 clinical trials conducted in three countries to validate the 
optimum use of melatonin to advance seasonal breeding patterns of a variety of breeds of 
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sheep. In order to define the optimum time for treatment in breeding flocks, ewes of three 
different breeds were treated with controlled-release 18-mg melatonin implants (Regulin®), 
with treatments commencing at various times ranging from 9 to 3 weeks, prior to joining with 
fertile rams. Overall, the studies presented in this paper showed that melatonin pretreatment 
of spring and early summer joined ewe flocks resulted in both a modest decrease in the num-
ber of barren ewes and an increase in the number of multiple births concluding that this treat-
ment strategy maximizes the potential advantages expected from the melatonin treatment.
2.6. Melatonin topical preparations
As mentioned previously, melatonin has shown antioxidant and immunological properties 
and therefore, it may be beneficial as a topical drug for the use against oxidative damage in 
the skin or even as a potential sun protection element, against UV-induced oxidative dam-
age. Melatonin skin penetration properties have been studied in alcoholic solutions, creams, 
in various vesicular approaches (liposomes and ethosomes), in undecanoic, lauric, and oleic 
acids.
The skin penetration properties of melatonin from three galenic preparations (0.01% in a 
cream and 0.01 and 0.03% in a solution) were investigated by the evaluation of the serum 
melatonin levels over a 24-h time period in a clinical study (15 healthy volunteers) conducted 
by a research group [46]. The cumulative melatonin serum values for each preparation were 
7.1, 8.6, and 15.7 pg/ml, respectively, showing that the alcoholic solution was superior to the 
cream formulation for melatonin delivery. The strongly lipophilic substance melatonin is able 
to penetrate through the skin, leading to dose- and galenic-dependent melatonin levels in the 
blood.
Novel ethanolic liposomes (ethosomes) bearing melatonin were evaluated for transdermal 
administration potential [47]. Melatonin loaded ethosomes were prepared and characterized 
for vesicular shape and surface morphology, vesicular size, entrapment efficiency, stability, in 
vitro skin permeation, and in vivo skin tolerability. The results suggested that ethosomes may 
offer a suitable approach for transdermal delivery of melatonin.
The effects of vehicles and enhancers on skin permeation and lag time were evaluated for a 
more effective transdermal delivery of melatonin [48]. Skin permeation study was conducted 
in Franz diffusion cells using excised hairless mouse skins and samples were analyzed by 
HPLC. As vehicles, ethanol (EtOH), polyethylene glycol 400 (PEG), or propylene glycol (PG) 
were used alone or mixed with a phosphate buffer. The results indicated that the use of binary 
vehicles could effectively modulate the skin permeability of melatonin (to the limited extent) 
and the lag time observed. As enhancers, fatty acids were used and when compared with the 
binary vehicles, the use of oleic acid drastically enhanced the skin permeation of melatonin as 
well as shortened its lag time.
Apart from being an established radioprotectant and anticancer agent [49], melatonin has also 
been found to counteract UV-induced solar damage, which includes the generation of reac-
tive oxygen species, skin aging, mitochondrial, and DNA damage [50]. The presence of mela-
tonin along with the UV filters could provide a synergistic effect for optimum sun protection 
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as topical application of melatonin along with vitamin E and C in human volunteers has been 
found to counteract ultraviolet induced erythema and the generation and adverse effects of 
free radical species [51]. Another research work [52] has dealt with the preclinical safety eval-
uation of the sunscreen formulation comprising of four US FDA approved UV filters; namely 
avobenzone, octinoxate, oxybenzone, titanium dioxide along with melatonin and pumpkin 
seed oil. The results obtained from this study indicated that the sunscreen formulation is 
nontoxic and safe in animal models and alongside with additional preclinical evaluations 
may serve as a basis for considering the formulation, as a potential candidate for further trials 
to establish its efficacy, tolerability, and applicability.
2.7. Transdermal patches
The transdermal delivery of melatonin could be a good route for its administration, given 
the variability of absorption, short biological half-life, and extensive first-pass metabolism of 
melatonin when administered orally. The main obstacle is the barrier nature of the stratum 
corneum of the skin that requires the right choice of a suitable vehicle, where the drug can be 
dissolved, then released, and finally penetrate the skin.
A research group [53] prepared and evaluated monolithic drug-in-adhesive type transdermal 
patches of melatonin using Eudragit E 100 as the adhesive polymer, containing penetration 
enhancers such as fatty alcohols, fatty acids, and terpenes. The results indicated that the addi-
tion of enhancers in the patch increased the permeation of melatonin through hairless rat 
skin. Decanol and undecanoic acid showed the maximum permeation of melatonin among 
the fatty alcohols and fatty acids, respectively, while menthol showed the maximum perme-
ation of melatonin among all the enhancers studied. The release profile of melatonin from the 
patches followed first order kinetics. A lag time of 4–6 h was observed before a steady-state 
flux of melatonin was reached.
The effect of transdermal in comparison to oral controlled-release and oral transmucosal 
drug delivery systems on plasma concentrations of melatonin and its principal metabolite 
(6-sulfatoxymelatonin (MT6s)) was evaluated in 12 human subjects using a crossover, single 
dose design [23]. The plasma concentrations of the parent drug and MT6s were measured 
by radioimmunoassay. Transdermal drug delivery resulted in a significant delay in sys-
temic drug levels and a gradual decline in drug delivery after patch removal (patch dosage 
forms were removed after 10 h of application), possibly due to the deposition of melatonin 
in the skin.
Other researchers suggested that transdermal melatonin may have advantages over fast-
release oral melatonin in improving sleep maintenance at adverse circadian cycles [54]. An 
experimental skin patch designed to deliver melatonin, such that plasma levels steadily 
increase for 6–8 h, and thus counteract the increasing circadian wake drive and improve day-
time sleep was administered to 8 healthy subjects (2.1 mg melatonin or placebo, randomized, 
double-blind, crossover study) 1 h before an 8 h daytime sleep opportunity (09:00–17:00 h). 
The results indicated that transdermal melatonin delivery was effective in elevating plasma 
melatonin levels for an extended duration during the daytime.
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Another group of researchers examined the pharmacokinetics of melatonin incorporated 
in solid lipid nanoparticles, administered by oral or transdermal route [18]. Solid lipid 
nanoparticles were used as a reservoir system, permitting a constant and prolonged release 
of melatonin. In comparison to the standard formulation of orally administered melatonin, 
the absorption and elimination after administration of the solid lipid nanoparticle-melatonin 
complexes through the transdermal route demonstrated to be slow and melatonin plasma 
levels above 50 pg/ml were maintained for at least 24 h. Therefore, these systems disclose a 
potential for the sustained delivery of melatonin.
3. Conclusions
In this chapter, a concise account of the different melatonin delivery routes is given. The 
choice of the most effective melatonin delivery system is circumstantial and depends on the 
dysfunction that needs to be treated. However, it seems that modified release formulations 
mimic closer the endogenous melatonin release pattern and thus a plethora of such systems 
are currently under thorough investigation.
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